We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Serum Metabolite Range Expanded Through Technology

By LabMedica International staff writers
Posted on 16 Mar 2011
Analytical technology has identified numerous blood metabolites in human serum that doctors can potentially look at to diagnose and treat health problems.

The metabolites that can be detected in human serum along with their respective concentrations and disease association have been revealed using a variety of techniques. More...


Scientists at the University of Alberta, (Edmonton, AB, Canada), have analyzed blood components to ascertain the most definitive human-serum metabolome to date. The data also includes chemicals found in the blood plasma. More than 20 scientists at six different institutions used state of the art technology to validate past research. The team also conducted its own laboratory experiments to break new ground on the content of human blood chemistry.

They used the following methods with mass spectroscopy (MS): gas chromatography (GC-MS); thin layer chromatography (TLC/GC-MS), liquid chromatography (LC-MS), ultrahigh performance liquid chromatography (UPLC-MS/MS), and direct flow injection (DFI -MS/MS) to identify, quantify and validate more than 4,000 plasma and serum metabolites. High-resolution nuclear magnetic resonance (NMR) spectroscopy was also used. The human serum metabolome database, created by the scientists is open access, allowing anyone to log on and find the expanded list of blood chemicals. Doctors can now tap into the collected wisdom of hundreds of blood-research projects done in the past by scientists all over the world

David Wishart, PhD, a lead author of the study, said, "Right now a medical doctor analyzing the blood of an ailing patient looks at something like 10 to 20 chemicals. We have identified 4,229 blood chemicals that doctors can potentially look at to diagnose and treat health problems. This is the most complete chemical characterization of blood ever done. We now know the normal values of all the detectable chemicals in blood. Doctors can use these measurements as a reference point for monitoring a patient's current and even future health." The study was published on February 16, 2011, in the journal Public Library of Science, PLoS One.

Related Links:

University of Alberta
The human serum metabolome database


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.